Bausch + Lomb is expanding its ophthalmology portfolio and pipeline, paying Novartis $1.75 billion to acquire a commercialized drug for dry eye disease along with two experimental eye products. The ...

Eye care company Bausch + Lomb (BLCO) said Friday it would pay $1.75 billion to acquire a portfolio of eye care products from Swiss healthcare giant Novartis (NVS), in a move that could help the ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter ...

Bausch + Lomb’s third quarter saw a positive market response, as the company posted growth across all major segments and met Wall Street’s revenue expectations. Management highlighted that strong ...

Eyecare company Bausch + Lomb (NYSE:BLCO) in Q1 CY2025 as sales rose 3.5% year on year to $1.14 billion. On the other hand, the company’s full-year revenue guidance of $5.05 billion at the midpoint ...

13 Poster Presentations Include Results from Second Pivotal Phase 3 Trial of Investigational Treatment NOV03 (Perfluorohexyloctane), as well as Data on XIPERE® (Triamcinolone Acetonide Injectable ...